Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68

• Published in: BioMed research international Vol. 2010; no. 2010; pp. 1 - 11
• Main Authors: Gentschev, Ivaylo, Donat, Ulrike, Hofmann, Elisabeth, Weibel, Stephanie, Adelfinger, Marion, Raab, Viktoria, Heisig, Martin, Chen, Nanhai G., Yu, Yong A., Stritzker, Jochen, Szalay, Aladar A.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Puplishing Corporation 01.01.2010; Hindawi Publishing Corporation; Dar al -Nasr -al-Llktruni; Hindawi Limited
• Subjects: Animals; Antigens, Neoplasm - metabolism; Biological and medical sciences; Biotechnology; Cancer; Cancer therapies; Cell Death; Cell Line, Tumor; Culture; Gynecology. Andrology. Obstetrics; Histocompatibility Antigens Class II - immunology; Human; Humans; Immune system; Lymph; Lymphatic Metastasis - pathology; Lymphocytes, Tumor-Infiltrating - immunology; Male; Male genital diseases; Medical sciences; Mice; Mice, Nude; Neoplasm Proteins - metabolism; Nephrology. Urinary tract diseases; Oncolytic Virotherapy - methods; Oncolytic Viruses - physiology; Prostate; Prostate cancer; Prostatic Neoplasms - immunology; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Prostatic Neoplasms - virology; Recombination, Genetic - genetics; Reduction; Remission Induction; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Vaccinia virus; Vaccinia virus - physiology; Virus Replication - physiology; Xenograft Model Antitumor Assays; Human; Prostate tumor; Chordopoxvirinae; Urinary system disease; Prostate disease; Recombinant virus; Orthopoxvirus; Rodentia; Regression; Malignant tumor; Metastasis; Oncolytic virus; Virus; Vaccinia virus; Vertebrata; Mammalia; Treatment; Mouse; Poxviridae; Animal; Male genital diseases; Cancer
• ISSN: 1110-7243; 2314-6133; 1110-7251; 2314-6141
• DOI: 10.1155/2010/489759

Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In the current study, we analyzed the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 against two human prostate cancer cell lines DU-145 and PC-3 in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 was able to infect, replicate in, and lyse these prostate cancer cells in culture. In DU-145 and PC-3 tumor xenograft models, a single intravenous injection with GLV-1h68 resulted in a significant reduction of primary tumor size. In addition, the GLV-1h68-infection led to strong inflammatory and oncolytic effects resulting in drastic reduction of regional lymph nodes with PC-3 metastases. Our data documented that the GLV-1h68 virus has a great potential for treatment of human prostate carcinoma.